Hemophilia, a group of bleeding disorders resulting from coagulation factor deficiency, poses significant clinical challenges. The NHP model of Prisys Biotechnologies offers an efficient and controlled method for studying the pathophysiology of hemophilia. The model is induced by anti-FVIII...
Send Inquiry
Product Introduction
Hemophilia is an X-linked inherited bleeding disorder that cause abnormal or exaggerated bleeding and poor blood clotting.
The major types of this condition are hemophilia A (also known as classic hemophilia or factor VIII deficiency) and hemophilia B (also known as Christmas disease or factor IX deficiency).
Current therapy for hemophilia is protein replacement using recombinant or plasma-derived clotting factors. Gene therapy treatments are a source of active research and hold promise for the future.
Cause: Hemophilia A is a genetic disorder caused by mutations in the F8 gene, which encodes coagulation factor VIII, an essential protein in the blood clotting cascade. The mutation results in a deficiency or dysfunction of factor VIII, leading to impaired blood clotting. Hemophilia A is an X-linked recessive disorder, which means that it predominantly affects males, while females are typically carriers of the mutation. The severity of hemophilia A varies depending on the specific mutation and the resulting level of factor VIII activity, with severe cases often presenting with spontaneous bleeding episodes, particularly into joints and muscles. Environmental factors, such as trauma or surgery, can exacerbate bleeding in affected individuals.
Diagnosing hemophilia A typically involves blood tests to measure factor VIII levels and genetic testing to identify mutations in the F8 gene. Treatment mainly consists of replacement therapy, where factor VIII is administered to manage bleeding episodes or as a prophylactic measure to prevent spontaneous bleeds. Advances in gene therapy also hold promise for more permanent solutions to the condition.
Advantages of Non-Human Primate (NHP) Models for Hemophilia A Research:
1.Close Genetic and Physiological Homology: NHPs share a high degree of genetic and physiological similarity with humans, including comparable coagulation systems, making them ideal for studying the molecular and cellular mechanisms of hemophilia A. This homology enhances the translational potential of research findings, particularly in the development of new treatments and gene therapies.
2.Longer Lifespan for Studying Long-Term Effects: The longer lifespan of NHPs compared to smaller animals allows for the investigation of chronic aspects of hemophilia A, including long-term outcomes of factor replacement therapies, complications such as joint damage, and the durability of gene therapy approaches.
3.Immunological Compatibility: NHPs possess an immune system that closely resembles that of humans, making them valuable for testing immune responses to factor VIII replacement therapies and gene therapies. This is particularly important for understanding the development of inhibitors, which are a major complication in hemophilia A treatment.
4.Translational Value for Therapeutic Development: NHPs serve as a critical model in bridging preclinical research to clinical trials, especially for advanced therapeutic approaches such as gene therapy. Their larger body size and similar physiology allow for the testing of therapeutic delivery methods and doses that are more relevant to humans.
Advantages of NHP Models Compared to Mouse Models for Hemophilia A Research:
1.Closer Genetic and Coagulation System Similarity: NHPs have a coagulation system more closely related to humans than mice, making them more accurate models for studying hemophilia A pathophysiology and for testing the efficacy of treatments like factor VIII replacement or gene therapies.
2.Better Model for Immune Responses: NHPs provide a more predictive model for studying the human immune response to factor VIII therapies, including the development of inhibitors, which are a significant complication in hemophilia A management. Mice, by contrast, often do not adequately mimic the human immune system, limiting the relevance of findings.
3.Greater Relevance for Gene Therapy Studies: Due to their larger size and more human-like genetic structure, NHP models offer more accurate evaluations of gene therapy approaches for hemophilia A. This includes assessing the delivery, integration, and long-term expression of therapeutic genes, which are more difficult to study effectively in mice.
4.Clinical Translation of Therapeutic Dosing and Delivery: The larger size and closer physiological resemblance of NHPs to humans allow for more accurate testing of therapeutic dosing and delivery systems, such as viral vectors used in gene therapy. This is particularly important for scaling up from preclinical studies to human clinical trials, where findings from NHP models are often more applicable than those from mouse models.
Study design and clinical endpoints
Study design：
Anti-FVIII ab induced hemophilia A in Cynomolgus monkeys
